Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

ICON Sponsors Industry-Wide Clinical Trials Survey to Support Transforming Trials Initiative


ICON plc, (NASDAQ:ICLR) a global provider of drug development solutions
and services to the pharmaceutical, biotechnology and medical device
industries, today announced the results from a new survey of
pharmaceutical executives and professionals by ICON and Pharma
Intelligence, which examines the key challenge of declining research and
development (R&D) efficiency.

A roundtable of pharmaceutical industry executives discussed the survey
findings, alongside the key challenges affecting the pharmaceutical
industry. The discussion enabled industry experts to identify the
potential for generating savings and improving trial efficiency, as well
as assessing how digital disruption is forcing change.

The challenges most frequently cited by survey respondents are patient
enrolment (56%), site start-up (43%) and regulatory approval delays and
changes (43%). Respondents also identified study start up, patient
recruitment and retention, and protocol development as three key areas
with the most potential for generating savings and efficiencies.

"ICON recognizes the challenges our customers are facing and is focused
on building our integrated site and patient network to improve trial
start up, as well as patient recruitment and retention." commented Dr.
Steve Cutler, Chief Executive Officer, ICON, on the survey findings.

Opinions of which technology trends will have the greatest impact on
clinical trial operations varied. 36% of survey respondents noted that
leveraging big data and AI technologies would have the most impact on
improving clinical trial efficiency. 35% reported that risk-based
approaches toward monitoring held greater opportunity for impact on
clinical development.

The survey demonstrates that industry have realised the need for a
holistic effort to transform trials, however, only one in five survey
respondents (22%) stated their organisation currently has an integrated
effort to drive clinical trials transformations. A further 83% of
respondents believe strategic partnerships with CROs will be important
to the success of clinical trials over the next five years.

Informed by the survey responses, the Improving Pharma R&D Efficiency
whitepaper proposes a three-part framework for guiding strategy in
transforming clinical trials.

  • Adopting a radical patient focus;
  • A greater use of adaptive clinical trials and other alternate trial
  • Automating data collection and analysis

The whitepaper argues that while adopting disparate tactics can improve
elements of clinical trial efficiency, the potential is even greater
when change is applied in a coordinated fashion to reimagine and
reinvent the R&D enterprise.

For further information on ICON's Transforming Trials initiative and the Improving
Pharma R&D Efficiency
whitepaper, please visit:

About the ICON Transforming Trials survey

Designed, conducted and analysed by Informa Engage using accepted market
research methods, 76 members of the Pharma Database responded to the
emailed survey between Oct 16 and 30, 2017. Half of respondents were
director level or higher, 24 percent managers and 26 percent clinical
trial professional personnel with no direct reports. A roundtable of
invited pharmaceutical industry executives was held at Informa offices
in London in November 2017 to discuss the survey results. The survey
data, and roundtable discussion, were complimented by extensive desk
research, in part conducted by ISR Research.

About ICON plc

ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 97 locations in 38 countries and
has approximately 13,380 employees. More information is at

This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at


View Comments and Join the Discussion!